Literature DB >> 21170668

Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21.

Yongci Zhang1, Ming Yang, Qing Ji, Dongmei Fan, Hui Peng, Chunzheng Yang, Dongsheng Xiong, Yuan Zhou.   

Abstract

Integrin αvβ3 plays a critical role in the survival and metastasis process of cancer cells. It is therefore desirable to develop new types of small molecule inhibitors of integrin αvβ3. IH1062 (3, 5-dichloro-phenylbiguanide) is a novel small molecule inhibitor of integrin αvβ3 that we have recently discovered. In this study, we investigated the induction effects of anoikis in human melanoma cell line M21 by IH1062, by detecting caspase activity, measuring the expression levels of apoptosis-related proteins, and performing the AnnexinV/PI apoptosis assay. Furthermore, we established a melanoma pulmonary metastasis mouse model in order to evaluate the suppression of metastasis by IH1062 in vivo. Our results demonstrate that IH1062 triggered human melanoma M21 cells to undergo anoikis by interrupting the attachment of M21 cells to extracellular matrix, reducing the phosphorylation of focal adhesion kinase, decreasing survivin and the ratio of Bcl-2/Bax proteins, and activating caspase cascades in vitro. Additionally, IH1062 showed markedly anti-metastatic effects in the pulmonary metastasis model in vivo, which makes it a promising lead to develop new drugs for anti-metastasis therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170668     DOI: 10.1007/s10637-010-9616-y

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  17 in total

1.  Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.

Authors:  Sylvie Maubant; Dominique Saint-Dizier; Morgane Boutillon; Francoise Perron-Sierra; Patrick J Casara; John A Hickman; Gordon C Tucker; Ellen Van Obberghen-Schilling
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

2.  Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.

Authors:  Yuan Zhou; Hui Peng; Qing Ji; Jing Qi; Zhenping Zhu; Chunzheng Yang
Journal:  Bioorg Med Chem Lett       Date:  2006-09-18       Impact factor: 2.823

3.  Integrin-mediated transcriptional activation of inhibitor of apoptosis proteins protects smooth muscle cells against apoptosis induced by degraded collagen.

Authors:  Karin von Wnuck Lipinski; Petra Keul; Nicola Ferri; Susann Lucke; Gerd Heusch; Jens W Fischer; Bodo Levkau
Journal:  Circ Res       Date:  2006-05-25       Impact factor: 17.367

4.  Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro.

Authors:  Eleonora Patsenker; Yury Popov; Matthias Wiesner; Simon L Goodman; Detlef Schuppan
Journal:  J Hepatol       Date:  2006-12-12       Impact factor: 25.083

5.  Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides.

Authors:  S Chatterjee; K H Brite; A Matsumura
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

6.  Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival.

Authors:  E Petitclerc; S Strömblad; T L von Schalscha; F Mitjans; J Piulats; A M Montgomery; D A Cheresh; P C Brooks
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

7.  Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.

Authors:  Yingshe Zhao; Richard Bachelier; Isabelle Treilleux; Philippe Pujuguet; Olivier Peyruchaud; Roland Baron; Philippe Clément-Lacroix; Philippe Clézardin
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

8.  Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis.

Authors:  Qizhen Cao; Weibo Cai; Gang Niu; Lina He; Xiaoyuan Chen
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

9.  Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells.

Authors:  Daniela Lössner; Claudia Abou-Ajram; Anke Benge; Ute Reuning
Journal:  Int J Biochem Cell Biol       Date:  2008-06-05       Impact factor: 5.085

10.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

View more
  5 in total

Review 1.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

2.  A natural bacterial-derived product, the metalloprotease arazyme, inhibits metastatic murine melanoma by inducing MMP-8 cross-reactive antibodies.

Authors:  Felipe V Pereira; Carla A Ferreira-Guimarães; Thaysa Paschoalin; Jorge A B Scutti; Filipe M Melo; Luis S Silva; Amanda C L Melo; Priscila Silva; Manoela Tiago; Alisson L Matsuo; Luiz Juliano; Maria A Juliano; Adriana K Carmona; Luiz R Travassos; Elaine G Rodrigues
Journal:  PLoS One       Date:  2014-04-30       Impact factor: 3.240

Review 3.  Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence.

Authors:  Shian-Ren Lin; Chia-Hsiang Chang; Che-Fang Hsu; May-Jwan Tsai; Henrich Cheng; Max K Leong; Ping-Jyun Sung; Jian-Chyi Chen; Ching-Feng Weng
Journal:  Br J Pharmacol       Date:  2019-11-27       Impact factor: 8.739

4.  Herbal compound Teng-Long-Bu-Zhong-Tang inhibits metastasis in human RKO colon carcinoma.

Authors:  Meng-Meng Wei; Shuang-Shuang Wang; Jia-Lu Zheng; Jin-Jun Chen; Xia Yan; Hong-Mei An; Bing Hu
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

Review 5.  Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.

Authors:  Timothy M Fan; Ryan D Roberts; Michael M Lizardo
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.